REACTIVATION OF RETINOPATHY OF PREMATURITY AFTER RANIBIZUMAB TREATMENT

2015136 citationsJournal Article

Authors

Abstract

The role of anti-VEGF treatment for ROP is still being evaluated. Although the shorter half-life of ranibizumab makes it an attractive option, reactivation of ROP is possible. Physicians and families should be aware of this to follow infants closely for an extended period of time.

Topics & Keywords

Retinopathy of Prematurity Studies Neonatal Health and Biochemistry Retinal Diseases and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Retina

Volume 35, Issue 4, pp. 675-680

DOI: 10.1097/iae.0000000000000578

Field-Weighted Citation Impact: 14.88